Literature DB >> 19717636

Calcification locates to transglutaminases in advanced human atherosclerotic lesions.

Hanke L Matlung1, Harald C Groen, Judith de Vos, Theo van Walsum, Aad van der Lugt, Wiro J Niessen, Jolanda J Wentzel, Ed Vanbavel, Erik N T P Bakker.   

Abstract

Transglutaminases play an important role in vascular smooth muscle cell-induced calcification in vitro. In this study, we determined whether these enzymes are also involved in human atherosclerotic calcification using nine carotid artery specimens obtained at endarterectomy. Sections of the carotid artery specimens were registered to micro-computed tomography images and stained for tissue-type transglutaminase, plasma transglutaminase factor XIIIA (FXIIIA), the N(epsilon)(gamma-glutamyl)lysine cross-link, and the macrophage marker CD68. Ex vivo micro-computed tomography revealed extensive calcification, which significantly correlated with the cross-link. FXIIIA was found to be the dominant transglutaminase, rather than tissue-type transglutaminase, although staining of both transglutaminases correlated with the cross-link. Staining for FXIIIA colocalized with CD68 at both the cellular and tissue level. In conclusion, areas of calcification locate to the presence and activity of transglutaminases in human atherosclerotic arteries. FXIIIA seems to be the dominant transglutaminase and may be derived from local macrophages. These results are consistent with the hypothesis that transglutaminases participate in the calcification process of human atherosclerotic arteries.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19717636      PMCID: PMC2751534          DOI: 10.2353/ajpath.2009.090012

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  17 in total

Review 1.  Transglutaminases: crosslinking enzymes with pleiotropic functions.

Authors:  Laszlo Lorand; Robert M Graham
Journal:  Nat Rev Mol Cell Biol       Date:  2003-02       Impact factor: 94.444

2.  Identification of factor XIII-A as a marker of alternative macrophage activation.

Authors:  D Töröcsik; H Bárdos; L Nagy; R Adány
Journal:  Cell Mol Life Sci       Date:  2005-09       Impact factor: 9.261

3.  The cellular response to transglutaminase-cross-linked collagen.

Authors:  David Y S Chau; Russell J Collighan; Elisabetta A M Verderio; Victoria L Addy; Martin Griffin
Journal:  Biomaterials       Date:  2005-11       Impact factor: 12.479

4.  Expression of tissue transglutaminase and elafin in human coronary artery: implication for plaque instability.

Authors:  Yoshihiko Sumi; Nobutaka Inoue; Hiroshi Azumi; Tadashi Seno; Masanori Okuda; Ken-ichi Hirata; Seinosuke Kawashima; Yoshitake Hayashi; Hiroshi Itoh; Mitsuhiro Yokoyama
Journal:  Atherosclerosis       Date:  2002-01       Impact factor: 5.162

5.  Localization of tissue transglutaminase in human carotid and coronary artery atherosclerosis: implications for plaque stability and progression.

Authors:  Z A Haroon; T Wannenburg; M Gupta; C S Greenberg; R Wallin; D C Sane
Journal:  Lab Invest       Date:  2001-01       Impact factor: 5.662

6.  Factor XIIIA transglutaminase crosslinks AT1 receptor dimers of monocytes at the onset of atherosclerosis.

Authors:  Said AbdAlla; Heinz Lother; Andreas Langer; Yasser el Faramawy; Ursula Quitterer
Journal:  Cell       Date:  2004-10-29       Impact factor: 41.582

7.  Small artery remodeling depends on tissue-type transglutaminase.

Authors:  Erik N T P Bakker; Carsten L Buus; Jos A E Spaan; Jop Perree; Anuradha Ganga; Titia M Rolf; Oana Sorop; Linda H Bramsen; Michael J Mulvany; Ed Vanbavel
Journal:  Circ Res       Date:  2004-11-18       Impact factor: 17.367

8.  Factor XIIIA mobilizes transglutaminase 2 to induce chondrocyte hypertrophic differentiation.

Authors:  Kristen A Johnson; David M Rose; Robert A Terkeltaub
Journal:  J Cell Sci       Date:  2008-06-10       Impact factor: 5.285

9.  Compensatory enlargement of human atherosclerotic coronary arteries.

Authors:  S Glagov; E Weisenberg; C K Zarins; R Stankunavicius; G J Kolettis
Journal:  N Engl J Med       Date:  1987-05-28       Impact factor: 91.245

10.  Plasma transglutaminase in hypertrophic chondrocytes: expression and cell-specific intracellular activation produce cell death and externalization.

Authors:  M Nurminskaya; C Magee; D Nurminsky; T F Linsenmayer
Journal:  J Cell Biol       Date:  1998-08-24       Impact factor: 10.539

View more
  9 in total

1.  Nitric oxide regulates tissue transglutaminase localization and function in the vasculature.

Authors:  Simran K Jandu; Alanah K Webb; Alina Pak; Baris Sevinc; Daniel Nyhan; Alexey M Belkin; Nicholas A Flavahan; Dan E Berkowitz; Lakshmi Santhanam
Journal:  Amino Acids       Date:  2011-10-08       Impact factor: 3.520

2.  Nitric oxide regulates non-classical secretion of tissue transglutaminase.

Authors:  Lakshmi Santhanam; Dan E Berkowitz; Alexey M Belkin
Journal:  Commun Integr Biol       Date:  2011-09-01

Review 3.  Transglutaminse 2 and EGGL, the protein cross-link formed by transglutaminse 2, as therapeutic targets for disabilities of old age.

Authors:  William Bains
Journal:  Rejuvenation Res       Date:  2013-12       Impact factor: 4.663

4.  Transglutaminase inhibitors attenuate vascular calcification in a preclinical model.

Authors:  Kelly E Beazley; Derek Banyard; Florence Lima; Stephanie C Deasey; Dmitry I Nurminsky; Mikhail Konoplyannikov; Maria V Nurminskaya
Journal:  Arterioscler Thromb Vasc Biol       Date:  2012-11-01       Impact factor: 8.311

5.  The redox state of transglutaminase 2 controls arterial remodeling.

Authors:  Jeroen van den Akker; Ed VanBavel; Remon van Geel; Hanke L Matlung; Bilge Guvenc Tuna; George M C Janssen; Peter A van Veelen; Wilbert C Boelens; Jo G R De Mey; Erik N T P Bakker
Journal:  PLoS One       Date:  2011-08-25       Impact factor: 3.240

Review 6.  Cystamine and cysteamine as inhibitors of transglutaminase activity in vivo.

Authors:  Thomas M Jeitner; John T Pinto; Arthur J L Cooper
Journal:  Biosci Rep       Date:  2018-09-05       Impact factor: 3.840

7.  Transglutaminase 2 limits the extravasation and the resultant myocardial fibrosis associated with factor XIII-A deficiency.

Authors:  Kathryn J Griffin; Laura M Newell; Kingsley R Simpson; Cora M L Beckers; Mark J Drinkhill; Kristina F Standeven; Lih T Cheah; Siiri E Iismaa; Peter J Grant; Christopher L Jackson; Richard J Pease
Journal:  Atherosclerosis       Date:  2019-12-17       Impact factor: 5.162

8.  Effect of transglutaminase 2 (TG2) deficiency on atherosclerotic plaque stability in the apolipoprotein E deficient mouse.

Authors:  Helen Williams; Richard J Pease; Laura M Newell; Paul A Cordell; Robert M Graham; Mark T Kearney; Christopher L Jackson; Peter J Grant
Journal:  Atherosclerosis       Date:  2009-11-20       Impact factor: 5.162

9.  Cellular-resolution 3D virtual histology of human coronary arteries using x-ray phase tomography.

Authors:  William Vågberg; Jonas Persson; Laszlo Szekely; Hans M Hertz
Journal:  Sci Rep       Date:  2018-07-20       Impact factor: 4.379

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.